IL1RAP

Product List

Creative Biolabs offers extensive range of high-quality IL1RAP CAR products (e.g., CAR vectors, virus particles, cell lines, proteins), as well as advanced solutions to support global customers’ CART projects.

Background

The interleukin 1 receptor accessory protein (IL1RAP), also known as IL1R3, is a co-receptor of the interleukin-1 receptor (IL1R1) and is integral in the IL-1 signaling transmission. The signaling pathways between IL-1RAP and IL-1 superfamily play an important role in tumor development and progression. IL-1RAP has been considered a promising target for the therapy of several hematological and solid cancers.

Associated Diseases

• Chronic myeloblastic leukemia (CML)
• Acute myeloblastic leukemia (AML)
• Non-small cell lung cancer (NSCLC)
• Gliomas
• Inflammatory diseases
• Others

Anti-IL1RAP CAR-T Services

Anti-IL1RAP CAR-T In Vitro Assays

Anti-IL1RAP CAR-T Expression Test

Creative Biolabs has established a variety of CAR detection products, as well as reliable assay methods to verify CAR expression levels.

Anti-IL1RAP CAR-T Proliferation Test

CART cells show specific proliferation stimulated by target cells, Creative Biolabs has developed a variety of detection methods to test the proliferation capability of CART cells to support our customers' CART projects, including but not limited to flow cytometry for Ki-67 or PCNA marker, cell proliferation dye staining test.

Fig.1 In vitro proliferation test of anti-IL1RAP CAR T-cells co-cultured with different AML cell lines by flow cytometry.¹

Phenotype Analysis of Anti-IL1RAP CAR-T

Phenotypic analysis is often used to detect the relevant functions of CART cells, such as the analysis of cell subpopulations and the analysis of cell states (e.g., activation, apoptosis, exhaustion). To characterize the relevant performance of CART cells, we have launched comprehensive phenotype tests to further provide customers with reliable and robust experimental data.

Fig.2 CD4+/CD8+ T subgroup analysis of anti-IL1RAP CAR-T cells generated from healthy donors or patients with AML.¹

Fig.3 Effector T (TE)/memory T (TM) cell subgroup analysis of anti-IL1RAP CAR-T cells generated from healthy donors or patients with AML.¹

Anti-IL1RAP CAR-T Cytokine Release Test

Creative Biolabs offers a comprehensive range of cytokine testing services, including intracellular and extracellular cytokine testing. We have established a variety of methods for customers to choose from, including flow cytokine detection, ELISA, multiple cytokine array, etc., and the types of cytokines that can be detected include not limited to IL-2, IL-6, IFN-y, TNF-a.

Fig.4 Intracellular IFN-γ analysis of anti-IL-1RAP CAR-T CD8+ or CD4+ cell subgroup co-cultured with different AML cell lines at 1:5 E:T ratio by flow cytometry.¹

Anti-IL1RAP CAR-T In Vitro Cytotoxicity Assay

In vitro cytotoxicity assay can preliminarily verify the specificity and effectiveness of CART cells against target cells, and provide strong support for the subsequent in vivo experimental design. Creative Biolabs supplies customers with a variety of cytotoxicity testing methods, such as LDH cytotoxicity test, flow cytometry cytotoxicity test, RTCA, etc.

Fig.5 In vitro cytotoxicity test of anti-IL1RAP CAR-T cells against different AML cell lines at indicated E:T ratios detected by flow cytometry.¹

Anti-IL1RAP CAR-T In Vivo Assays

Anti-IL1RAP CAR-T Cell Therapy Animal Models

For in vivo validation, we offer a variety of animal models (e.g., CDX, PDX models) for our customers to choose from, as well as optimized experimental design to provide better efficacy services.

Fig.6 Schematic diagram of AML xenograft model experiment design for IL1RAP efficacy test.¹

Efficacy Test of Anti-IL1RAP CAR-T

Creative Biolabs provides customers with robust in vivo efficacy tests to evaluate the specificity and effectiveness of CART cells against tumor cells.

Fig.7 In vivo efficacy of anti-IL1RAP CAR-T cells in AML xenograft NSG mouse models evaluated by BLI monitoring.¹

For CART development, we provide a one-stop service to fully evaluate the therapeutic potential and safety of CAR T cells. In addition to the above evaluation, we also offer the following in vivo tests:

Toxicity Evaluation Anti-IL1RAP CAR-T

Persistence of anti-IL1RAP CAR-T cell

Reference

1. Trad, Rim, et al. "Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia." Journal for Immunotherapy of Cancer 10.7 (2022).